Kpti stock forecast market data in the KPTI stock forecast

Market data in the KPTI stock forecast points to RSI levels near 55, suggesting neutral momentum with potential for an upward swing if upcoming trial results beat expectations. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage biotechnology company focusing on producing selinexor, a nuclear exportin 1 inhibitor. Through a phase 3 trial, KPTI hopes to add endometrial cancer to the list of diseases for which selinexor is now licensed, in addition to multiple myeloma, which is approved for treatment in later lines of therapy in the US. Karyopharm Therapeutics has a consensus price target of $34.00, representing about 432.9% upside from its current price of $6.38. The KPTI stock forecast is sensitive to biotech regulatory announcements; a favorable industry trend could lift peer valuations and KPTI along with them in the short-term.